Evaluation of Dose-Intense Ifosfamide, with and Without Edatrexate, in Adults with Sarcoma

Ephraim S. Casper; Gary M. Schwartz; Denis Leung; Alison Sugarman; Joseph R. Bertino

doi:10.1080/13577149977758

Sarcoma (Jan 1999)

Evaluation of Dose-Intense Ifosfamide, with and Without Edatrexate, in Adults with Sarcoma

Ephraim S. Casper,
Gary M. Schwartz,
Denis Leung,
Alison Sugarman,
Joseph R. Bertino

Affiliations

Ephraim S. Casper: Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NewYork, NY 10021, USA
Gary M. Schwartz: Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NewYork, NY 10021, USA
Denis Leung: The Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, NewYork, NY 10021, USA
Alison Sugarman: Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NewYork, NY 10021, USA
Joseph R. Bertino: Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NewYork, NY 10021, USA

DOI: https://doi.org/10.1080/13577149977758
Journal volume & issue: Vol. 3, no. 2
pp. 121 – 127

Abstract

Read online

Purpose. To define the maximally tolerated dose (MTD) of ifosfamide when given with G-CSF on an every other week schedule, and to define the MTD of edatrexate that can be given every two weeks with an intense schedule of ifosfamide.

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal